# Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT04478695** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 1 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** AMG 330
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04478695
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-29
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Amgen Decision
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478695, "Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04478695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*